Discover the power of our Patient-derived cell (PDC) model and high content imaging platform
Lengthy and costly drug development programs hamper the development of new oncology drugs and result in high attrition rates.
To accelerate new compounds to the clinic and ensure each patient is treated with the most effective drug for their disease, patient-relevant in vitro models that can be easily expanded and rapidly tested for response are needed.
Imagen has developed an end-to-end platform based on proprietary PDC models and high content imaging read-outs that can be used by patient, clinicians, and drug developers to:
Download our service portfolio datasheet to learn more